The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.94
Bid: 0.00
Ask: 21.95
Change: 0.00 (0.00%)
Spread: 3.45 (18.649%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 18.94
NANO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Statement

3 Dec 2020 07:00

RNS Number : 3534H
Nanoco Group PLC
03 December 2020
 

3 December 2020

NANOCO GROUP PLC

("Nanoco", the "Group", or the "Company")

 

AGM Statement

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other specific nanomaterials emanating from our technology platform, will hold its Annual General Meeting ("AGM") later this morning in a virtual format due to the restrictions caused by the Coronavirus pandemic. Details of the arrangements were included in the Notice of Meeting issued on 17 November 2020.

Dr Christopher Richards, Nanoco's Chairman, will make the following statement in respect of the first four months of the financial year ending 31 July 2021 ('the Period').

 

Operational and trading update

We continue to deliver R&D services under a number of development programmes with different customers in the sensing and display markets, the most significant of which is the work with ST Microelectronics N.V. ('ST Micro'). Good progress has been made on this project during the Period and we are now negotiating its potential next phase.

On 25 November 2020, we also announced that we had successfully secured a project grant from Innovate UK, the UK's innovation agency, to develop a heavy metal-free quantum dot testing kit for the accurate and rapid visual detection of SARSCoV-2 ("Covid-19"). This funding creates a potential third opportunity for future revenue, on top of the Group's activities in Sensing and Display, whilst maintaining Nanoco's cash runway.

Financial performance in the Period has been in line with the Board's expectations. The Board remains focussed on new commercial revenues to sustain the Group's organic activities in H2 FY21 and beyond, with contingency plans in place if needed.

 

Samsung Litigation Update

The litigation against Samsung is proceeding in line with expectations. A trial date has been set for October 2021, but this may experience delay due to the Covid-19 pandemic. As expected, Samsung have submitted requests for Inter Partes Reviews ('IPR's) of the patents relevant to the case with the US Patent Office and these are being managed as a normal part of the litigation process. The Board's confidence remains high that we will obtain a positive outcome.

 

- Ends -

 

For further information, please contact:

 

Nanoco Tel: +44 (0) 161 603 7900

Brian Tenner, Chief Executive Officer

Liam Gray, UK FD and Company Secretary

Caroline Watson, Investor Relations Manager

cwatson@nanocotechnologies.com

 

MHP Communications Tel: +44 (0) 20 3128 8570

Reg Hoare / Giles Robinson / Pete Lambie

nanoco@mhpc.com

 

Notes for editors:

 

About Nanoco Group plc

Nanoco (LSE: NANO) harnesses the power of nano-materials. Nano-materials are materials with dimensions typically in the range 1 - 100 nm. Nano-materials have a range of useful properties, including optical and electronic. Quantum dots are a subclass of nano-material that have size-dependent optical and electronic properties. The Group produces quantum dots. Within the sphere of quantum dots, the Group exploits different characteristics of the quantum dots to target different performance criteria that are attractive to specific markets or end-user applications such as the Display and Electronics markets. One of the interesting properties of quantum dots is photoluminescence: the emission of longer wavelength light upon excitation by light of a shorter wavelength. The colour of light emitted depends on the particle size. Nanoco's CFQD® quantum dots are free of cadmium and other toxic heavy metals, and can be tuned to emit light at different wavelengths across the visible and infrared spectrum, rendering them useful for a wide range of applications including displays, lighting and biological imaging.

Nanoco has non-exclusive manufacturing and marketing licensing agreements in display with The Dow Chemical Company and Wah Hong Industrial Corporation of Taiwan. Nanoco was founded in 2001 and is headquartered in Manchester, UK, with a US subsidiary, Nanoco Inc., in Concord, MA. Nanoco continues to build out a world-class, patent-protected IP portfolio generated both by its own innovation engine.

Nanoco is listed on the Main Market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocogroup.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMEAEAAEASEFAA
Date   Source Headline
3rd Jul 20195:50 pmRNSHolding(s) in Company
27th Jun 201912:15 pmRNSHolding(s) in Company
26th Jun 20193:20 pmRNSDirector/PDMR Shareholding
26th Jun 201911:45 amRNSHolding(s) in Company
25th Jun 201912:45 pmRNSHolding(s) in Company
24th Jun 20193:45 pmRNSHolding(s) in Company
24th Jun 20193:30 pmRNSHolding(s) in Company
24th Jun 20193:30 pmRNSHolding(s) in Company
21st Jun 20197:00 amRNSUS Customer partnership update
12th Jun 201910:25 amRNSBlock listing Interim Review
7th Jun 20194:00 pmRNSDirector/PDMR Shareholding
3rd May 20197:00 amRNSDirector/PDMR Shareholding
2nd May 20196:09 pmRNSDirector/PDMR Shareholding
18th Apr 20194:55 pmRNSDirector/PDMR Shareholding
17th Apr 20193:20 pmRNSHolding(s) in Company
17th Apr 20191:22 pmRNSHolding(s) in Company
16th Apr 20195:08 pmRNSHolding(s) in Company
11th Apr 20193:38 pmRNSHolding(s) in Company
11th Apr 20197:00 amRNSDirector/PDMR Shareholding
9th Apr 20197:00 amRNSInterim Results
1st Apr 201911:40 amRNSHolding(s) in Company
12th Mar 20197:00 amRNSDirectorate Changes
4th Mar 20197:00 amRNSNotice of Results
31st Jan 20197:00 amRNSChange of Auditor
25th Jan 20197:00 amRNSContract extension signed
4th Jan 201912:18 pmRNSHolding(s) in Company
4th Jan 20197:00 amRNSPartnership with Plessey Semiconductors
24th Dec 20187:00 amRNSMilestone Achieved
13th Dec 20183:33 pmRNSResult of AGM
13th Dec 20187:00 amRNSAGM Statement
10th Dec 20184:00 pmRNSBLOCKLISTING SIX-MONTHLY RETURN
3rd Dec 201811:18 amRNSDirector Declaration
3rd Dec 20187:00 amRNSHolding(s) in Company
30th Nov 20184:35 pmRNSPrice Monitoring Extension
16th Nov 20184:53 pmRNSHolding(s) in Company
15th Nov 20187:00 amRNSDirector/PDMR Shareholding
13th Nov 20188:15 amRNSAnnual Report and Notice of AGM
7th Nov 20181:33 pmRNSDirector/PDMR Shareholding
24th Oct 20187:00 amRNSHolding(s) in Company
17th Oct 20181:47 pmRNSDirector/PDMR Shareholding
16th Oct 201811:14 amRNSDirector/PDMR Shareholding
16th Oct 20187:00 amRNSPreliminary Results
3rd Oct 20187:00 amRNSHolding(s) in Company
24th Sep 20185:00 pmRNSHolding(s) in Company
17th Sep 20187:00 amRNSHolding(s) in Company
17th Sep 20187:00 amRNSHolding(s) in Company
11th Sep 20187:00 amRNSInvestor day
5th Sep 20182:21 pmRNSHolding(s) in Company
17th Aug 201811:28 amRNSHolding(s) in Company - Replacement
15th Aug 20184:47 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.